In situ adenovirus vaccination engages T effector cells against cancer - Wikidata - wikimedia - TriplyDB

In situ adenovirus vaccination engages T effector cells against cancer

In situ adenovirus vaccination engages T effector cells against cancer

http://www.wikidata.org/entity/Q37306292

about

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells The influence of innate and pre-existing immunity on adenovirus therapy Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models.Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus.T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation Oncolytic vaccines.Fighting Cancer with Mathematics and Viruses.Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer.An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance.Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.Oncolytic Viral Therapy for Mesothelioma.Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients.Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.Propolis extracts from the northern region of Thailand suppress cancer cell growth through induction of apoptosis pathways.Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy.Tumor Regression and Cure Depends on Sustained Th1 Responses

P2860

Q30899557-EBFF8AF3-0F14-44A4-8CE2-F8B0A6437C4C Q33645792-5580EF0D-2F12-4DC1-96B0-0DE8E4ACA478 Q33655401-020E3697-9182-47C3-B8A3-E1679F0E1439 Q33968361-FC87E5F3-DEE1-408A-9EF1-3B4D27CDD89B Q34183436-E3846AC0-61B4-4C26-8C2F-2A7E90D9B9E2 Q34988018-EBDDB530-49F5-47FE-B931-BE13A77A8B52 Q35238258-798EF509-56ED-4027-A139-C0B78526679A Q35285768-CBDBD019-37FA-43CD-9F59-F42B0BC0DD5F Q35594838-1A7E4C4F-FE89-4543-A51D-FA1E489FC27B Q36582785-605B77A7-1557-4376-9D1E-83C30F074403 Q36936462-74457465-81E5-4E55-AF33-BB661C1BD7DB Q38152474-8EB7A5FA-1E45-4C5B-973D-4C45C5012672 Q38612646-C780243F-5621-446E-A3EE-50009FDCEA18 Q38893420-A2CD67FD-C834-4761-8252-D2ECEC998EB7 Q38992973-767D9BFD-5E81-415B-A461-E7BCC3309C38 Q39308911-52CC5616-972C-4B2A-A544-81378354E0C6 Q39532576-FA1D411F-4926-4116-A337-C547224B52F1 Q40051845-E34E5B06-948B-4B7D-A268-95C2441191DE Q45869559-776B7787-F59F-40EA-8206-4ACD34615091 Q50865520-48FDFD87-733D-44F3-BD3B-E9F73A6DB0ED Q51477466-1023638D-5A54-4266-A96A-AD3F43C68E0A Q51847569-0D7E4A7B-4937-4BE0-B23A-5C8FF8469379 Q56876356-0976C0CA-D677-486F-9F0A-EDDBEE1586E6

P2860

In situ adenovirus vaccination engages T effector cells against cancer

http://www.wikidata.org/entity/Q37306292

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

In situ adenovirus vaccination engages T effector cells against cancer

@en

In situ adenovirus vaccination engages T effector cells against cancer.

@nl

type

label

In situ adenovirus vaccination engages T effector cells against cancer

@en

In situ adenovirus vaccination engages T effector cells against cancer.

@nl

prefLabel

In situ adenovirus vaccination engages T effector cells against cancer

@en

In situ adenovirus vaccination engages T effector cells against cancer.

@nl

P1433

Q37306292-07F10FB6-EE0A-4347-8495-EA199C166FD1

P1476

Q37306292-D2541EF0-EF87-4F36-85AF-6BE2B9B2ADE5

P2093

Q37306292-01D3E133-C99C-4CB1-941E-5E570D526D0C

Q37306292-0233A8AA-44F4-4EA4-89C5-3330DF312BBE

Q37306292-332ADB7E-B4B9-427B-8503-DA40EDC4CFD0

Q37306292-850D859C-8CC0-47D0-B131-69924311B966

Q37306292-926D197A-6FAB-4F90-A8AF-12D9F090979B

Q37306292-9CFFDB20-9C6A-4414-9B08-F59CCC3B9CF0

Q37306292-B00CB0AA-B062-4D6F-A522-B6A01B50F913

Q37306292-B42511EB-04CD-47F2-A521-B49DCFCCEBDE

Q37306292-E8939C7B-7879-4B7E-ACE0-4AB02217F43D

Q37306292-EF1EEBDA-421E-4723-94DE-872D3957F0FF

P2860

Q37306292-0C6D3171-1331-43B5-99B4-CA76A2CD0969

Q37306292-0F2EF8B4-8379-4E85-AF87-9680F4F49703

Q37306292-116DD521-A121-48B4-B19E-D2BD0DDB9420

Q37306292-13F69117-E46D-47E3-B16B-AB4FF15C2EC1

Q37306292-1533AE30-CC4C-4F82-9FDA-8104F44769D1

Q37306292-1BAC5BA2-E098-4FFE-8684-A05CF4ACFAC7

Q37306292-20BB33A3-5728-4DC6-942A-72DE14B001E6

Q37306292-20C6000F-7538-4436-A4C3-9915BA62DCF6

Q37306292-20CFE26E-4DD1-48E3-AA19-53287D318705

Q37306292-2E7C56D8-4778-4F3C-A298-7F7CE97E8381

P304

Q37306292-9621692F-56B0-4475-AFAF-FC04AFDD3EBD

P31

Q37306292-F018E51A-15BA-431F-A0B7-C49EBFDE23D7

P356

Q37306292-D9331BC5-9D67-492C-99A0-96BB9A587223

P407

Q37306292-EFC251DC-6D3E-46FB-A1F2-6D02AD754557

P433

Q37306292-F92C2470-DC33-44AA-B942-E4ACD331B2DB

P478

Q37306292-9287B11F-1806-438F-A924-D0A77695D1FA

P50

Q37306292-60EF8405-96A2-4AB6-BB2A-D1A996F16D45

P577

Q37306292-49C936BE-03FD-4180-9664-E0711009BC20

P5875

Q37306292-855859D7-E4A7-479C-94E5-4DB1ED0E1F6D

P698

Q37306292-F86E072F-0B6F-438D-AEC8-B779E4CD5BFB

P921

Q37306292-5CDB5C30-AAD1-4740-B070-F10B1E0351BC

P932

Q37306292-A4690C2E-BCE6-4EC4-BC8B-4FD1A71A742F

P356

J.VACCINE.2009.03.074

P1433

P1476

In situ adenovirus vaccination engages T effector cells against cancer

@en

P2093

André Lieber

http://www.w3.org/2001/XMLSchema#string

Karl-Erik Hellström

http://www.w3.org/2001/XMLSchema#string

Khajornsak Tragoolpua

http://www.w3.org/2001/XMLSchema#string

Mary Lenora Disis

http://www.w3.org/2001/XMLSchema#string

Robert Strauss

http://www.w3.org/2001/XMLSchema#string

Roma Christine Yumul

http://www.w3.org/2001/XMLSchema#string

Sebastian Tuve

http://www.w3.org/2001/XMLSchema#string

Steve Roffler

http://www.w3.org/2001/XMLSchema#string

Ying Liu

http://www.w3.org/2001/XMLSchema#string

Zong-Yi Li

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunoediting: from immunosurveillance to tumor escape

TGF-beta: a master of all T cell trades

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response

Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.

Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers.

Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

Cross-presentation in viral immunity and self-tolerance.

P304

4225-4239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2009.03.074

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey D Jacobs

P577

2009-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26252256

http://www.w3.org/2001/XMLSchema#string

P698

19481312

http://www.w3.org/2001/XMLSchema#string

P921

P932

2727281

http://www.w3.org/2001/XMLSchema#string